View Financial Health이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 피드백을 환영합니다!Inventiva 배당금배당금 기준 확인 0/6Inventiva 배당금을 지급한 기록이 없습니다.주요 정보n/a배당 수익률n/a지급 비율업계 평균 수익률1.8%다음 배당금 지급일n/a전 배당일n/a주당 배당금n/a주당 순이익-€1.293년 후 배당 수익률 예측0%최근 배당금 업데이트업데이트 없음모든 업데이트 표시Recent updatesInventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with LanifibranorMay 15+ 1 more updateInventiva S.A. Provides Update on its Clinical Trial NATiV3Feb 16Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024Dec 23+ 1 more updateInventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development ProgramDec 21Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024Aug 27Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023Jul 29Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLDJun 14Insufficient new directors Mar 04Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023Feb 15Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated CirrhosisJan 06Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated CirrhosisJan 05Inventiva S.A., Annual General Meeting, Jan 25, 2023Jan 03Inventiva Announces Lucy Lu as the Director of its Board of DirectorsNov 22Inventiva Provides Update on Development of cedirogant by AbbVieOct 31Insufficient new directors Aug 12Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2DJul 08Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022Jun 11Inventiva S.A., Annual General Meeting, May 19, 2022Apr 12No longer forecast to breakeven Apr 11Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with NashMar 10Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022Feb 15Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb InitiationFeb 01Forecast to breakeven in 2024 Jan 13결제의 안정성과 성장
Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with LanifibranorMay 15+ 1 more update
Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development ProgramDec 21
Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLDJun 14
Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated CirrhosisJan 06
Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated CirrhosisJan 05
Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2DJul 08
Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022Jun 11
Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with NashMar 10
Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb InitiationFeb 01